Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ai |
RCV002223447 | SCV002501020 | likely pathogenic | not provided | 2021-05-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002223447 | SCV003336796 | pathogenic | not provided | 2022-03-28 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with LPL-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Trp417*) in the LPL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LPL are known to be pathogenic (PMID: 11334614). |
Genomic Medicine Center of Excellence, |
RCV003988878 | SCV004805514 | pathogenic | Hyperlipoproteinemia, type I | 2024-03-25 | criteria provided, single submitter | research | |
Mayo Clinic Laboratories, |
RCV002223447 | SCV005413826 | pathogenic | not provided | 2024-07-18 | criteria provided, single submitter | clinical testing | PM2, PS4_supporting, PVS1 |